Development of a Multivalent, PrPSc-Specific Prion Vaccine through Rational Optimization of Three Disease-Specific Epitopes

Vaccine

Volumn 32, Issue 17, 2014, Pages 1988-1997

  Marciniuk, Kristen ^a,b   Määttänen, Pekka ^b   Taschuk, Ryan ^a,b   Airey, T Dean ^c   Potter, Andrew ^b   Cashman, Neil R ^c   Griebel, Philip ^a,b   Napper, Scott ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Disease Specific Epitopes; Prion diseases; Protein Misfolding; Self Epitope; Vaccine

Indexed keywords

EPITOPE; PRION PROTEIN; PRION VACCINE; UNCLASSIFIED DRUG;

ALGORITHM; ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA SHEET; COMPUTER MODEL; CONTROLLED STUDY; DRUG SAFETY; DRUG SPECIFICITY; FEMALE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PREDICTION; PRION DISEASE; PRIORITY JOURNAL; SHEEP;

DISEASE-SPECIFIC EPITOPES; PRION DISEASES; PROTEIN MISFOLDING; SELF-EPITOPE; VACCINE;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; EPITOPES, B-LYMPHOCYTE; FEMALE; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; PRION DISEASES; PROTEIN STRUCTURE, SECONDARY; PRPSC PROTEINS; SHEEP; VACCINES; VACCINES, SUBUNIT;

EID: 84896313899     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.027     Document Type: Article

References (38)

1. Griffith J. Self-replication and scrapie. Nature 1967, 215:1043-1044.
2. Prusiner S. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-144.
3. Aguzzi A., Sigurdson C., Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008, 3:11-40.
4. Silveira J.R., Caughey B., Baron G.S. Prion protein and the molecular features of transmissible spongiform encephalopathy agents. Curr Top Microbiol Immunol 2004, 284:1-50.
5. Baeten L.A., Powers B.E., Jewell J.E., Spraker T.R., Miller M.W. A Natural Case of Chronic Wasting Disease in a Free-ranging Moose (Alces alces shirasi). J Vet Dis 2008, 43:309-314.
6. Collinge J. Prion diseases of humans and animals: Their causes and molecular basis. Ann. Rev. Neurosci 2001, 24:519-550.
7. Geshwind M.D. Clinical trials for prion disease: difficult challenges, but hope for the future. Lancet Neurol 2009, 8(4):304-306.
8. Sigurdsson E.M., Brown D.R., Daniels M., Kascsak R.J., Kascsak R., Carp R., Meeker H.C., Frangione B., Wisniewski T. Immunization delays the onset of prion disease in mice. Am J Pathol 2002, 161:13-17.
9. Hanan E., Priola S.A., Solomon B. Antiaggregating antibody raised against human PrP 106-126 recognizes pathological and normal isoforms of the whole prion protein. Cellular and Molecular Neurobiology 2001, 21(6):693-703.
10. Koller M.F., Grau T., Christen P. Induction of antibodies against murine full-length prion protein in wildtype mice. J Neuroimmunol 2002, 132(1-2):113-116.
11. Rosset M.B., Ballerini C., Gregoire S., Metharom P., Carnaud C., Aucouturier P. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 2004;, 172(9):5168-5174.
12. Polymenidou M., Heppner F.L., Pellicioli E.C., Urich E., Miele G., Braun N., Wopfner F., Schatzl H.M., Becher B., Aguzzi A. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci U S A 2004, 101:14670-14676.
13. Schwarz A., Kratke O., Burwinkel M., Riemer C., Schultz J., Henklein P., Bamme T., Baier M. Immunization with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003, 350:187-189.
14. Gilch S., Wopfner F., Renner-Muller I., Kremmer E., Bauer C., Wolf E., Brem G., Groschup M.H., Schatzl H.M. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem 2003, 278(20):18524-18531.
15. Cashman N.R., Loertscher R., Nalbantoglu J., Shaw I., Kascsak R.J., Bolton D.C., Bendheim P.E. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 1990, 61(1):185-192.
16. Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S, Kellermann O. NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells.
17. Arsenault R.J., Li Y., Potter A., Griebel P.J., Kusalik A., Napper S. Induction of ligand-specific PrP (C) signaling in human neuronal cells. Prion 2012, 6(5):477-488.
18. Solforosi L., Criado J.R., McGavern D.B., Wirz S., Sánchez-Alavez M., Sugama S., DeGiorgio L.A., Volpe B.T., Wiseman E., Abalos G., Masliah E., Gilden D., Oldstone M.B., Conti B., Williamson R.A. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004, 303(5663):1514-1516.
19. Li L., Napper S., Cashman N.R. Immunotherapy for Prion Disease: Opportunities and Obstacles. Immunotherapy 2010, 2:269-282.
20. Paramithiotis E., Pinard M., Lawton T., LaBoissiere S., Leathers V.L., Zou W.Q., Estey L.A., et al. A prion protein epitope selective for the pathologically misfolded conformation. Nature Medicine 2003, 9(7):893-899.
21. Li L., Guest W., Plotkin S.S., Cashman N.R. Immunological mimicry of PrPC-PrPSC interactions: antibody-induced PrP misfolding. Protein Eng Des Sel 2009, 22(8):523-529.
22. Sc-specific antibody responses. Vaccine 2010, 28:981-988.
23. Cashman N.R. Antibodies and epitopes specific to misfolded prion protein. EP Patent 2012, 2403871.
24. Cashman N.R., Plotkin S.S., Guest W.C. Methods and systems for predicting misfolded protein epitopes. EP Patent 2011, 2342220.
25. Sigurdson C.J., Aguzzi A. Chronic wasting disease. Biochim Biophys Acta 2007, 1772:610-618.
26. Gossert A.D., Bonjour S., Lysek D.A., Fiorito F., Wuthrich K. Prion protein NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci U S A 2005, 102:646-650.
27. Larsen J.E.P., Lund O., Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Research 2006, 2:2.
28. Manns J., Barker C., Attah-Poku S. The design, production, purification, and testing of a chimeric antigen protein to be used as an immunosterilant in domestic animals. Can J Chem 1997, 75:829-833.
29. Harland R.J., Potter A.A., van Drunen-Little-van den Hurk S, Van Donkersgoed J, Parker MD, Zamb TJ, Janzen ED. The effect of subunit or modified live bovine herpesvirus-1 vaccines on the efficacy of a recombinant Pasteurella haemolytica vaccine for the prevention of respiratory disease in feedlot calves. Can Vet J 1992, 33:734-741.
30. Li L., Coulthart M.B., Balachandran A., Chakrabartty A., Cashman N.R. Species barriers for chronic wasting disease by in vitro conversion of prion protein. Biochem Biophys Res Commun 2007, 364(4):796-800.
31. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J., Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003, 422:80-83.
32. Sigurdsson E.M., Sy M.S., Li R., Scholtzova H., Kascsak R.J., Kascsak R., Carp R., Meeker H.C., Frangione B., Wisniewski T. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 2003, 336:185-187.
33. Goni F., Prelli F., Schreiber F., Scholtzova H., Chung E., Kascsak R., Brown D.R., Sigurdsson E.M., Chabalgoity J.A., Wisniewski T. High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 2008, 153:679-686.
34. Sonati T, Reimann RR, Falsig J, Baral PK, O'Connor T, Hornemann S, Yaganoglu S, Li B, Herrmann US, Wieland B, Swayampakula M, Rahman MH, Das D, Kav N, Riek R, Liberski PP, James MN, Aguzzi A. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature 2013; Jul 31.
35. Jardine J., Julien J.P., Menis S., Ota T., Kalyuzhniy O., McGuire A., Sok D., Huang P.S., MacPherson S., Jones M., Nieusma T., Mathison J., Baker D., Ward A.B., Burton D.R., Stamatatos L., Nemazee D., Wilson I.A., Schief W.R. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340(6133):711-716.
36. Joshi H., Lewis K., Singharoy A., Ortoleva P.J. Epitope engineering and molecular metrics of immunogenicity: A computational approach to VLP-based vaccine design. Vaccine 2013, 31:4841-4847.
37. Uversky V.N. Targetting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. Expert Rev Proteomics 2010, 7(4):543-564.
38. James T.L., Liu H., Ulyanov N.B., Farr-Jones S., Zhang H., Donne D.G., et al. Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. PNAS USA 1997, 94(19):10086-10091.